| 2.61 0.06 (2.35%) | 05-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.33 | 1-year : | 3.67 |
| Resists | First : | 2.85 | Second : | 3.15 |
| Pivot price | 2.76  |
|||
| Supports | First : | 2.37 | Second : | 1.97 |
| MAs | MA(5) : | 2.6 |
MA(20) : | 2.79 |
| MA(100) : | 3.09 |
MA(250) : | 3.03 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 27.3 |
D(3) : | 24.6 |
| RSI | RSI(14): 36.3 |
|||
| 52-week | High : | 6.19 | Low : | 1.66 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TCRT ] has closed above bottom band by 22.0%. Bollinger Bands are 36.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.72 - 2.74 | 2.74 - 2.75 |
| Low: | 2.46 - 2.48 | 2.48 - 2.5 |
| Close: | 2.58 - 2.61 | 2.61 - 2.64 |
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
Fri, 01 May 2026
Alaunos Therapeutics (TCRT) director awarded 6,515 shares at $2.59 - Stock Titan
Fri, 01 May 2026
Alaunos Therapeutics (TCRT) director receives 6,274-share stock grant in lieu of fees - Stock Titan
Fri, 01 May 2026
Director at Alaunos (TCRT) receives 6,032-share stock award - Stock Titan
Thu, 30 Apr 2026
MSN Money - MSN
Thu, 30 Apr 2026
Alaunos Therapeutics (NASDAQ: TCRT) details board, pay and ownership in 10-K/A - Stock Titan
Thu, 23 Apr 2026
Alaunos Therapeutics (TCRT) Moat Analysis | Q4 2023: EPS Misses Estimates - Stability Report - Xã Châu Thành
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 1.89e+006 (%) |
| Held by Institutions | 4 (%) |
| Shares Short | 34 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.22e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -30 % |
| Return on Assets (ttm) | 233.3 % |
| Return on Equity (ttm) | -92.4 % |
| Qtrly Rev. Growth | 5000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0.5 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.33 |
| Dividend | 0 |
| Forward Dividend | 14160 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|